ENEA

LEADOPTIK Receives Investment from Applied Ventures

Retrieved on: 
Tuesday, June 20, 2023
Hair, Surgeon, Travel, Biopsy, Cancer, Orbital angular momentum of light, Needle, Applied Materials, Lung, Venture, SOSV, Silicon, SAN, Engineering, Principal, YP, ENEA, FDA, Medical imaging

SAN JOSE, Calif., June 20, 2023 /PRNewswire/ -- LEADOPTIK Inc., a Silicon Valley-based medical imaging company today announced that it has secured venture capital funding from Applied Ventures, LLC. This new injection of capital augments a recently announced $5 million over-subscribed seed venture funding round led by MetaVC Partners with participation from SOSV, Sony Innovation Fund, TSVC, ENEA, and others. This will allow LEADOPTIK to move to the next stage of product development, including FDA approval, on the path to commercialization.

Key Points: 
  • SAN JOSE, Calif., June 20, 2023 /PRNewswire/ -- LEADOPTIK Inc. , a Silicon Valley-based medical imaging company today announced that it has secured venture capital funding from Applied Ventures , LLC.
  • This will allow LEADOPTIK to move to the next stage of product development, including FDA approval, on the path to commercialization.
  • "We are excited to be an investor in LEADOPTIK," said Yuan-Ping (YP) Huang, Principal of Applied Ventures, the venture capital arm of Applied Materials, Inc. "We see metamaterials, particularly optical metasurfaces and flat optics based on materials engineering capabilities, enabling a new wave of innovative products that can be smaller, faster, and less costly than traditional optics."
  • "Applied Ventures is an outstanding deep-tech investor and technology advisor for us," stated Reza Khorasaninejad, Founder and CEO of LEADOPTIK.

LEADOPTIK Raises $5 Million in Series Seed Funding to Advance Early Lung Cancer Detection with Cutting-Edge Imaging Technology

Retrieved on: 
Monday, May 22, 2023
Hair, Surgeon, Travel, Biopsy, Survival, Cancer, Lung cancer, Orbital angular momentum of light, BioWare, Needle, SOSV, Silicon, Patient, SAN, Diagnosis, ENEA, FDA, World Health Organization, Medical imaging, Dropbox

LEADOPTIK is developing a miniaturized imaging system ushering in a new level of real-time imaging deep inside human lungs and enabling early diagnoses of cancer.

Key Points: 
  • LEADOPTIK is developing a miniaturized imaging system ushering in a new level of real-time imaging deep inside human lungs and enabling early diagnoses of cancer.
  • According to the World Health Organization, lung cancer is responsible for the highest number of cancer-related deaths worldwide.
  • Early detection and diagnosis are vital to a patient's survival; however, there are currently no effective approaches for diagnosing cancer at its earliest stages.
  • "The work that LEADOPTIK is doing in developing novel imaging technologies to address lung cancer detection is a perfect example of that."

EU-funded TRICK Project Will Use Quadrans Blockchain Technology for Product Traceability

Retrieved on: 
Wednesday, October 5, 2022
Italian National Agency for the Deaf, Union, Data collection, Method, Information, IOT, National Agency of Ukraine for Civil Service, Royal commission, Implementation, GA, Information management, Research, Food industry, Confidentiality, Partnership, Goal, Industry, TRICK, ADM, Blockchain, Economic development, ENEA, Blockchain-based database, Intention, Awareness, Development, Work, Work breakdown structure, Emerging technologies, GLOBE, Government, European Commission, Deliverable, European Union's scientific cooperation beyond the bloc, Solution, Interoperability, Documentation, Cryptocurrency, Medical device, EU

Within the TRICK Consortium there is the Quadrans Foundation , a non-profit organisation under Swiss law that conducts research and development of the Quadrans blockchain: an open-source, public, decentralised smart-contract-based blockchain with a specific focus on the needs of industry, complex supply chains, and IoT devices.

Key Points: 
  • Within the TRICK Consortium there is the Quadrans Foundation , a non-profit organisation under Swiss law that conducts research and development of the Quadrans blockchain: an open-source, public, decentralised smart-contract-based blockchain with a specific focus on the needs of industry, complex supply chains, and IoT devices.
  • For its unique characteristics, the Quadrans blockchain has been chosen to be a central technology for the TRICK infrastructure and the Quadrans Team, together with UBITECH , is committed to leading the "Design and Implementation of Blockchain Integration and Interoperability" (Work Package 3 Tasks 3.3).
  • As many businesses are concerned with data privacy and confidentiality, the TRICK Project will use Quadrans blockchain technology and smart contracts to ensure all information is protected and secured.
  • In December this year, all TRICK members will demonstrate the platform's developments to the European Union, during which the Quadrans Team will present the use of Truebit in detail.

Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022

Retrieved on: 
Wednesday, September 7, 2022
Acromegaly, SRL, Patient, ENEA, Degenerative disease, Neurosurgery, Northwestern Health Sciences University, Poster, Oregon Health & Science University, Physician, Union, RCT, Sequoyah, European, Adult, Oregon Health Plan, Lead, Congress, FACE, Capsule, Pharmaceutical industry, MD

Dr. Tracy Cunningham, Chief Medical Officer of Amryt,commented: These data provide important information for physicians when switching patients from injectable SRLs to Mycapssa.

Key Points: 
  • Dr. Tracy Cunningham, Chief Medical Officer of Amryt,commented: These data provide important information for physicians when switching patients from injectable SRLs to Mycapssa.
  • These patients were then followed for an additional nine months in the randomized controlled treatment (RCT) phase.
  • At the end of the RCT phase patients were provided the option to continue into an open label phase and receive Mycapssa.
  • Response was defined as the time-weighted average of IGF-1

New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly

Retrieved on: 
Tuesday, September 6, 2022
Carpal tunnel syndrome, COVID-19, Fatigue, ENEA, Pain, Securities Act of 1933, Research, Liver, SAN, Medication, Evolve, Drug Quality and Security Act, Injection, Carcinoid syndrome, Hormone, GLOBE, Metabolism, Degenerative disease, Patient, Time, Glucose, Adenoma, SEC, Universiade, Arthritis, FDA, Growth hormone, Drug discovery, Intellectual property, Sleep apnea, Annual report, Arthralgia, Congenital hyperinsulinism, SRL, SST2, Securities Exchange Act of 1934, Form 10-K, Lipid metabolism, Pituitary adenoma, Sequoyah, Vocal cords, GH, Marketing, Needle, Congenital adrenal hyperplasia, Doctor of Philosophy, Advance, Wilms' tumor, Heart, ACTH, Human, Medical school, Therapy, Clinical trial, OLE, Pharmaceutical industry, Endocrinology, Acromegaly, MD

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT program, presented new data from the planned two-year interim analysis of the ACROBAT Advance open label extension (OLE) study at the 35th Brazilian Congress of Endocrinology and Metabolism (CBEM).

Key Points: 
  • This preliminary data, combined with the preference participants had for oral paltusotine over the injected standard-of-care, speaks to the potential paltusotine may have as a long-term therapy for acromegaly.
  • Dr. Gadelha will present an additional poster of the Advance OLE data at the European Neuroendocrine Association (ENEA) meeting.
  • That presentation, titled Long-Term Treatment with Oral Paltusotine for Acromegaly: Results from the ACROBAT Advance study will be made on September 9th.
  • In Phase 2 trials, paltusotine maintained IGF-1 levels in acromegaly patients who switched from injectable depot medications to once-daily paltusotine.